Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 5/2019

01-10-2019 | Lung Cancer | LUNG CANCER

Association of Variants in IL6-Related Genes with Lung Cancer Risk in Moroccan Population

Authors: Houda Kaanane, Nezha Senhaji, Hind Berradi, Nadia Benchakroun, Abdellatif Benider, Mehdi Karkouri, Hicham El Attar, IGOT CASA, Meriem Khyatti, Sellama Nadifi

Published in: Lung | Issue 5/2019

Login to get access

Abstract

Purpose

Lung cancer is known to be a complex multifactorial disease, involving both genetic and environmental factors. The study of the different signaling pathways and the identification of the genes involved, will contribute to further understanding the pathogenesis of the disease, thus allowing the development of appropriate targeted treatments. Recently, the link between cancer and inflammation has become more evident and inflammation has been proposed as the seventh hallmark of cancer. Previous studies have suggested that key cytokines involved in inflammation may have an important role in the etiology of lung cancer. The aim of this study was to investigate whether common variants in inflammation-related genes: IL-6, IL6-R, and IL6-ST, influence lung cancer risk in Moroccan population.

Materials and Methods

Single nucleotide polymorphisms (SNPs) in IL-6, IL6-R, and IL6-ST genes were assessed in 120 controls and 120 patients with confirmed lung cancer diagnosis. Genotyping analysis was performed with the TaqMan® allelic discrimination technology. The results were analyzed using SPSS 24.0 software.

Results

Among the studied SNPs, we found a significant association for the IL-6 (rs2069840) (OR = 1.63; 95% confidence interval 1.08–2.47; p = 0.01). No significant association was observed for the remaining SNPs of IL-6R (rs2228145) and IL-6ST (rs2228044) genes.

Conclusion

Our results suggest the IL-6 (rs2069840) polymorphism may influence the occurrence of lung cancer in Moroccan patients.
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6):394–424CrossRefPubMed
2.
Chin LJ et al (2008) A SNP in a let-7 microRNA complementary site in the KRAS 3′UTR increases non-small cell lung cancer risk. Cancer Res 68(20):8535–8540PubMedPubMedCentralCrossRef
3.
Jiang Y-Q, Zhou Z-X, Ji Y-L (2014) Suppression of EGFR-STAT3 signaling inhibits tumorigenesis in a lung cancer cell line. Int J Clin Exp Med. 7(8):2096–2099PubMedPubMedCentral
4.
Wolf J, Rose-John S, Garbers C (2014) Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 70(1):11–20PubMedCrossRef
5.
Lacroix M et al (2015) Novel insights into interleukin 6 (IL-6) cis- and trans-signaling pathways by differentially manipulating the assembly of the IL-6 signaling complex. J Biol Chem 290(45):26943–26953PubMedPubMedCentralCrossRef
6.
7.
Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374(Pt 1):1–20PubMedPubMedCentralCrossRef
8.
Schaper F, Rose-John S (2015) Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth Factor Rev 26(5):475–487PubMedCrossRef
9.
Kitamura H et al (2017) Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Sci 108(10):1947–1952PubMedPubMedCentralCrossRef
10.
Bai L, Yu H, Wang H, Su H, Zhao J, Zhao Y (2013) Genetic single-nucleotide polymorphisms of inflammation-related factors associated with risk of lung cancer. Med. Oncol 30(1):414PubMedCrossRef
11.
Kiyohara C, Horiuchi T, Takayama K, Nakanishi Y (2014) Genetic polymorphisms involved in the inflammatory response and lung cancer risk: a case-control study in Japan. Cytokine 65(1):88–94PubMedCrossRef
12.
Reyes-Gibby CC, Wang J, Spitz M, Wu X, Yennurajalingam S, Shete S (2013) Genetic variations in interleukin-8 and interleukin-10 are associated with pain, depressed mood, and fatigue in lung cancer patients. J Pain Symptom Manage 46(2):161–172PubMedCrossRef
13.
Desai S, Laskar S, Pandey BN (2013) Autocrine IL-8 and VEGF mediate epithelial-mesenchymal transition and invasiveness via p38/JNK-ATF-2 signalling in A549 lung cancer cells. Cell Signal 25(9):1780–1791PubMedCrossRef
14.
15.
Grivennikov SI, Karin M (2011) Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 70(Suppl 1):i104–i108PubMedCrossRef
16.
17.
Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5(10):749–759PubMedCrossRef
18.
Grivennikov SI, Karin M (2010) Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 20(1):65–71PubMedCrossRef
19.
20.
21.
Ellingsgaard H et al (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17(11):1481–1489PubMedPubMedCentralCrossRef
22.
Wunderlich FT et al (2010) Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab 12(3):237–249PubMedCrossRef
23.
24.
März P, Otten U, Rose-John S (1999) Neural activities of IL-6-type cytokines often depend on soluble cytokine receptors. Eur J Neurosci 11(9):2995–3004PubMedCrossRef
25.
Belluco C et al (2003) 174 G%3eC polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin Cancer Res 9(6):2173–2176PubMed
26.
Tan D et al (2005) Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol 174(2):753–756PubMedCrossRef
27.
Bao S, Yang W, Zhou S, Ye Z (2008) Relationship between single nucleotide polymorphisms in −174G/C and −634C/G promoter region of interleukin-6 and prostate cancer. J Huazhong Univ Sci Technol [Med Sci] 28(6):693CrossRef
28.
Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Malecka-Panas E (2009) Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci 54(3):683–689PubMedCrossRef
29.
Yang M, Li C, Li M (2014) Association of interleukin-6 (-174 G/C) polymorphism with the prostate cancer risk: a meta-analysis. Biomed Rep 2(5):637–643PubMedPubMedCentralCrossRef
30.
31.
Bhat IA et al (2015) Significant impact of IL-6 -174G/C but inverse relation with -634 C/G polymorphism in patients with non-small cell lung cancer in Kashmiri population. Immunol Investig 44(4):349–360CrossRef
32.
Nie W, Xue L, Sun G, Ning Y, Zhao X (2014) Interleukin-6 −634C/G polymorphism is associated with lung cancer risk: a meta-analysis. Tumor Biol 35(5):4581–4587CrossRef
33.
Banday MZ, Balkhi HM, Sameer AS, Chowdri NA, Haq E (2017) Strong association of interleukin-6 −174G/C promoter single nucleotide polymorphism with a decreased risk of colorectal cancer in ethnic Kashmiri population: a case control study. Tumour Biol 39(3):1010428317695940PubMedCrossRef
34.
Eaton KD, Romine PE, Goodman GE, Thornquist MD, Barnett MJ, Petersdorf EW (2018) Inflammatory gene polymorphisms in lung cancer susceptibility. J Thorac Oncol 13(5):649–659PubMedPubMedCentralCrossRef
35.
Sales-Marques C et al (2017) Genetic polymorphisms of the IL6 and NOD2 genes are risk factors for inflammatory reactions in leprosy. PLoS Negl Trop Dis 11(7):e0005754PubMedPubMedCentralCrossRef
36.
Szpecht D et al (2017) The significance of IL-1β +3953C%3eT, IL-6 -174G%3eC and -596G%3eA, TNF-α -308G%3eA gene polymorphisms and 86 bp variable number tandem repeat polymorphism of IL-1RN in bronchopulmonary dysplasia in infants born before 32 weeks of gestation. Cent Eur J Immunol 42(3):287–293PubMedPubMedCentralCrossRef
37.
Stephens KE et al (2017) Associations between genetic and epigenetic variations in cytokine genes and mild persistent breast pain in women following breast cancer surgery. Cytokine 99:203–213PubMedPubMedCentralCrossRef
38.
De Mattia E et al (2018) Association of STAT-3 rs1053004 and VDR rs11574077 with FOLFIRI-related gastrointestinal toxicity in metastatic colorectal cancer patients. Front Pharmacol 9:367PubMedPubMedCentralCrossRef
39.
Ahmed S, Hussain S, Ammar A, Jahan S, Khaliq S, Kaul H (2017) Interleukin 6 receptor (IL6-R) gene polymorphisms underlie susceptibility to rheumatoid arthritis. Clin Lab 63(9):1365–1369PubMed
40.
Topchieva LV, Kurbatova IV, Dudanova OP, Sokolovskaya AA, Shipovskaya AA (2018) IL6R gene polymorphic variant rs2228145(C %3eA) as a marker of genetic liability to nonalcoholic steatohepatitis in the Russian population of Karelia. Bull Exp Biol Med 165(1):64–68PubMedCrossRef
41.
Parisinos CA et al (2018) Variation in interleukin 6 receptor gene associates with risk of Crohn’s disease and ulcerative colitis. Gastroenterology 155(2):303–306.e2PubMedCrossRef
42.
Mitrokhin V et al (2017) Association between interleukin-6/6R gene polymorphisms and coronary artery disease in Russian population: influence of interleukin-6/6R gene polymorphisms on inflammatory markers. J Inflamm Res 10:151–160PubMedPubMedCentralCrossRef
43.
Senhaji N et al (2016) Association of inflammatory cytokine gene polymorphisms with inflammatory bowel disease in a Moroccan cohort. Genes Immun 17(1):60–65PubMedCrossRef
44.
López-Mejías R et al (2013) No evidence of association between functional polymorphisms located within IL6R and IL6ST genes and Henoch-Schönlein purpura. Tissue Antigens 82(6):416–419PubMedCrossRef
45.
46.
Han L et al (2017) Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status. Lung Cancer 114:79–89PubMedCrossRef
47.
Sun L et al (2014) Low incidence of IL6ST (gp130) mutations in exon 6 in lung cancer of a Chinese cohort. Cancer Genet 207(7–8):291–298PubMedCrossRef
48.
49.
Grivennikov S, Karin M (2008) Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 13(1):7–9PubMedCrossRef
50.
Song L, Rawal B, Nemeth JA, Haura EB (2011) JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther 10(3):481–494PubMedPubMedCentralCrossRef
51.
Yao Z et al (2010) TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA 107(35):15535–15540PubMedCrossRefPubMedCentral
Metadata
Title
Association of Variants in IL6-Related Genes with Lung Cancer Risk in Moroccan Population
Authors
Houda Kaanane
Nezha Senhaji
Hind Berradi
Nadia Benchakroun
Abdellatif Benider
Mehdi Karkouri
Hicham El Attar
IGOT CASA
Meriem Khyatti
Sellama Nadifi
Publication date
01-10-2019
Publisher
Springer US
Published in
Lung / Issue 5/2019
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-019-00261-0

Other articles of this Issue 5/2019

Lung 5/2019 Go to the issue

LUNG CANCER

Increasing Numbers and Reported Adverse Events in Patients with Lung Cancer Undergoing Inpatient Lung Biopsies: A Population-Based Analysis

LUNG IMAGES

Mucocele Presenting as Polypoid Bronchoscopic Lesion with Post-Obstructive Pneumonia

Letter to the Editor

A Prognostic Score for Brain Metastases of Non-small-cell Lung Cancer in the Era of Precision Medicine

COUGH

Impact of Cough and Unmet Needs in Chronic Cough: A Survey of Patients in Korea

Airway Biology

Elevated Levels of Alveolar Nitric Oxide May Indicate Presence of Small Airway Inflammation in Patients with Inflammatory Bowel Disease

ELECTRONIC CIGARETTES

Electronic Cigarette Advertising Impacts Adversely on Smoking Behaviour Within a London Student Cohort: A Cross-Sectional Structured Survey
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits